Merck to Complete Acquisition of Cidara Therapeutics

Merck completed a cash tender offer to acquire Cidara Therapeutics, paying $221.50 per share with 27,149,333 shares tendered (≈85.96%), and will complete a merger to acquire the remaining shares and delist Cidara. The deal brings CD388, a Phase 3 long-acting antiviral candidate for preventing symptomatic influenza in high-risk individuals, into Merck’s respiratory portfolio; Merck expects the acquisition to be accounted for as an asset acquisition, increasing 2026 R&D expense by approximately $9.0 billion (≈$3.65/share) and reducing GAAP and non-GAAP EPS by about $0.30 in the first 12 months.

Analysis

Market structure: Merck (MRK) materially expands its respiratory franchise by acquiring CD388 (CDTX) for $221.50/share, concentrating upside in a potentially season-long, strain-agnostic influenza prophylactic. Immediate winners are large integrated pharma (MRK) and distributors able to commercialize at scale; losers are small-cap antivirals and niche vaccine substitutes whose market share in high-risk cohorts could be displaced. Pricing power will accrue to firms that can bundle prophylaxis with existing respiratory portfolios, constraining entrants’ launch economics and likely compressing small-biotech M&A premia over 12–36 months.

Risk assessment: Key tail risks are Phase 3 failure or unexpected safety signals from ANCHOR (regulatory risk), manufacturing/CMC complexity for a novel DFC (operational), and litigation or accounting scrutiny over the $9.0bn asset charge (financial). Short-term (days–weeks) equity volatility is most likely; medium-term (3–12 months) credit/earnings guidance revisions could surface; long-term (2–5 years) commercial outcomes hinge on ANCHOR readout and payer acceptance. Catalysts: ANCHOR readout, FDA interactions, and Merck’s integration guidance; missed milestones would negate the acquisition rationale.

Trade implications: Tactical: buy MRK on >3–5% pullbacks; consider 12–18 month OTM call exposure (10–15% OTM LEAPs sized 0.5–1% notional) to capture approval upside while limiting cash. Use a pairs approach: long MRK (2–3% portfolio) vs short IBB or a basket of small respiratory biotech names (1–2%) to express scale-over-nimbleness. Credit: buy 5–7yr MRK IG bonds if spread widens >15bp for carry; hedge equity exposure with modest put protection if MRK drops >8% intraday.

Contrarian angles: The market may over-penalize MRK for a one-time $9bn GAAP charge (≈$3.65/share allocation) and a modest $0.30 EPS hit in year one, creating asymmetric upside if ANCHOR succeeds. Historically, big-pharma buys of late-stage antivirals (e.g., acquirer success stories) trade sideways until clinical proof — a 20–30% trough could be a buy zone. Unintended risks: payer pushback on season-long pricing and integration deprioritization of other respiratory programs could limit upside; size positions accordingly.

Key Decisions for Investors

• Establish a 2–3% long position in MRK within 1–4 weeks; add to 4–6% total if MRK sells off >5% intraday post-announcement (target 12–36 month horizon to capture approval commercialization optionality).
• Allocate 0.5–1% notional to MRK 12–18 month OTM calls (≈10–15% OTM LEAPs) as a leveraged upside play; trim on a positive ANCHOR readout or if implied volatility rises >40% from current levels.
• Initiate a pairs trade: long MRK (2% portfolio) funded by short IBB or a small-cap respiratory-biotech basket (1–2%) to capture rotation to scale; rebalance on ANCHOR readout or if MRK outperforms by >15% relative to IBB.
• Purchase 5–7 year Merck investment-grade bonds (size 1–3% portfolio) if spreads widen >15 basis points versus pharma IG median to lock in yield; use this as a defensive hedge against equity volatility.